title: Microbiological and pharmacokinetic studies of acyl demycinosyltylosin and related tylosin derivatives.
abstract: A series of tylosins and acyl derivatives of 23-O-demycinosyltylosin (DMT) were initially tested for in vitro antibacterial activity and serum levels in squirrel monkeys (po) and mice (iv). Overall, the DMT compounds were more active in vitro than the tylosins. Two tetraacylated DMTs, Sch 37644 and Sch 38646, were selected from the initial studies for further evaluation and compared to erythromycin and A-56268 (6-O-methyl erythromycin). Sch 37644 and Sch 38646 were 2 to 8-fold less potent in vitro against Gram-positive bacteria than erythromycin and A-56268. In squirrel monkeys, Sch 37644 (AUC, 19.7 micrograms.hour ml) and A-56268 (21.6 micrograms.hour/ml) had similar serum levels following po administration of 20 mg/kg, while Sch 38646 (11.8 micrograms.hour/ml) and erythromycin (1.5 micrograms.hour/ml) had lower levels. In mice administered 200 mg/kg orally, Sch 37644 (AUC, 19.4 micrograms.hour/ml) and Sch 38646 (15.4 micrograms.hour/ml) had higher serum levels than erythromycin (5.7 micrograms.hour/ml). A-56268 was the most active po macrolide in mouse protection studies (PD50S) against Staphylococci and Streptococci, while Sch 37644 and Sch 38646 were similar to erythromycin.
authors: Schering-Plough Research, Bloomfield, NJ 07003.
authors: A F
authors: AF
authors: Cacciapuoti
authors: D
authors: D
authors: Loebenberg
authors: E L
authors: EL
authors: Moss
authors: F W
authors: FW
authors: Menzel
authors: J A
authors: JA
authors: Rudeen
authors: L R
authors: LR
authors: Naples
authors: C L
authors: CL
authors: Cramer
authors: R S
authors: RS
authors: Hare
authors: A K
authors: AK
authors: Mallams
authors: G H
authors: GH
authors: Miller
mesh_terms: D000818:Animals; D017291:Clarithromycin; D004917:Erythromycin / Q000031:analogs & derivatives / Q000493:pharmacokinetics / Q000494:pharmacology; D008297:Male; D051379:Mice; D015394:Molecular Structure; D012453:Saimiri; D013203:Staphylococcal Infections / Q000517:prevention & control; D013210:Staphylococcus / Q000187:drug effects*; D013290:Streptococcal Infections / Q000517:prevention & control; D013291:Streptococcus / Q000187:drug effects*; D015645:Tylosin / Q000031:analogs & derivatives* / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use
chemical_list: C066132:Sch 38646; C066133:Sch 37644; D004917:Erythromycin; D017291:Clarithromycin; D015645:Tylosin